Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Addict Behav. 2023 Mar 11;143:107688. doi: 10.1016/j.addbeh.2023.107688

Table 1.

Baseline demographic and clinical characteristics

Measure Total (n = 30) TAU (n = 10) PE (n = 10) PE+ (n = 10)
Age, years 38.1 (7.9) 44.7 (8.9) 33.8 (4.6) 35.9 (5.2)
Female, N (%) 19 (63.3) 7 (70.0) 6 (60.0) 6 (60.0)
White, N (%) 29 (96.7) 10 (100) 9 (90.0) 10 (100)
Education, years 13.3 (1.5) 13.6 (2.0) 13.6 (1.3) 12.8 (1.1)
Employed full-time, N (%) 6 (20.0) 2 (20.0) 2 (20.0) 2 (20.0)
Duration of illicit opioid use, years 7.4 (7.3) 9.1 (8.9) 4.6 (4.6) 8.2 (7.4)
Ever overdosed, N (%) 10 (33.3%) 3 (30.0%) 4 (40.0%) 3 (30.0%)
MOUD medication
 Buprenorphine, N (%) 17 (56.7%) 6 (60.0%) 6 (60.0%) 5 (50.0%)
 Daily dose, mg 15.6 (5.6) 17.0 (6.2) 16.3 (5.7) 13.2 (5.0)
 Methadone, N (%) 13 (43.3%) 4 (40.0%) 4 (40.0%) 5 (50.0%)
 Daily dose, mg 92.2 (42.3) 103.8 (44.2) 55.8 (17.3) 112.0 (44.4)
Duration of MOUD, years 4.5 (4.1) 5.2 (5.2) 5.3 (4.4) 3.0 (2.2)
Index trauma
 Sexual assault, N (%) 10 (33.3%) 4 (40.0%) 2 (20.0%) 4 (40.0%)
 Physical assault, N (%) 8 (26.7%) 4 (40.0%) 3 (30.0%) 1 (10.0%)
 Witnessed injury or death, N (%) 4 (13.3%) 1 (10.0%) 1 (10.0%) 2 (20.0%)
 Learned about injury or death, N (%) 3 (10.0%) 1 (10.0%) 0 (0%) 2 (20.0%)
 Accident, N (%) 2 (6.7%) 0 (0%) 1 (10.0%) 1 (10.0%)
 Combat, N (%) 1 (3.3%) 0 (0%) 1 (10.0%) 0 (0%)
 Other, N (%) 2 (6.7%) 0 (0%) 2 (20.0%) 0 (0%)
History of PTSD treatment, N (%) 18 (60.0%) 5 (50.0%) 5 (50.0%) 8 (80.0%)
SUD other than OUD 21 (70.0%) 6 (60.0%) 8 (80.0%) 7 (70.0%)
Cigarette smoker, N (%) 23 (76.7%) 6 (60.0%) 9 (90.0%) 8 (80.0%)
Lifetime Suicide Attempt 17 (56.7%) 6 (60.0%) 5 (50.0%) 6 (60.0%)
Lifetime Panic Disorder 18 (60.0%) 6 (60.0%) 4 (40.0%) 8 (80.0%)
Lifetime Bipolar Disorder 16 (53.3%) 6 (60.0%) 4 (40.0%) 6 (60.0%)
Lifetime Generalized Anxiety Disorder 15 (50.0%) 6 (60.0%) 3 (30.0%) 6 (60.0%)
Lifetime Major Depressive Disorder 13 (43.3%) 4 (40.0%) 5 (50.0%) 4 (40.0%)
CAPS-5 41.5 (8.1) 38.9 (8.7) 41.4 (8.6) 44.1 (6.9)
PCL-5 56.0 (10.9) 57.1 (11.4) 51.4 (12.4) 59.5 (7.7)
BAI 26.2 (11.8) 31.7 (11.3) 21.5 (9.6) 25.3 (13.1)
BDI-II 32.3 (9.9) 34.4 (8.8) 29.7 (6.5) 32.8 (13.4)

Note. TAU = continued MOUD treatment as usual; PE = Prolonged Exposure therapy; PE+ = PE with financial incentives delivered contingent upon PE session attendance; MOUD = medications for opioid use disorder; PTSD = posttraumatic stress disorder; SUD = substance use disorder; OUD = opioid use disorder; CAPS-5 = Clinician Administered PTSD Scale for DSM-5; PCL-5 = PTSD Checklist for DSM-5; BAI = Beck Anxiety Inventory; BDI-II = Beck Depression Inventory. Values represent mean (SD) unless otherwise indicated.